US6410561B1 - Amide derivatives and nociceptin antagonists - Google Patents
Amide derivatives and nociceptin antagonists Download PDFInfo
- Publication number
- US6410561B1 US6410561B1 US09/646,781 US64678100A US6410561B1 US 6410561 B1 US6410561 B1 US 6410561B1 US 64678100 A US64678100 A US 64678100A US 6410561 B1 US6410561 B1 US 6410561B1
- Authority
- US
- United States
- Prior art keywords
- methyl
- amino
- quinolyl
- benzamide hydrochloride
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 B.C.C1=CN=C2C=CC=CC2=C1.CC.CC.CC.CCCC.CN.CNC(C)=O.[2*]C Chemical compound B.C.C1=CN=C2C=CC=CC2=C1.CC.CC.CC.CCCC.CN.CNC(C)=O.[2*]C 0.000 description 24
- UFKSGZRBJXCBIF-UHFFFAOYSA-N C.CC.CCCCC Chemical compound C.CC.CCCCC UFKSGZRBJXCBIF-UHFFFAOYSA-N 0.000 description 3
- HHUIDJNWXJTSJX-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=CN=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=CN=CC=C3)C=CC2=N1.Cl HHUIDJNWXJTSJX-UHFFFAOYSA-N 0.000 description 2
- MKKYFRVDLLFKRX-UHFFFAOYSA-N CC1=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)=CC=C1Cl.Cl Chemical compound CC1=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)=CC=C1Cl.Cl MKKYFRVDLLFKRX-UHFFFAOYSA-N 0.000 description 2
- BDDMAWARYNEZHN-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C([N+](=O)[O-])C=C4)C=CC=C3)C=C2/C(N)=C\1 Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C([N+](=O)[O-])C=C4)C=CC=C3)C=C2/C(N)=C\1 BDDMAWARYNEZHN-UHFFFAOYSA-N 0.000 description 2
- BMIIHKGOMQTXIW-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(F)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(F)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl BMIIHKGOMQTXIW-UHFFFAOYSA-N 0.000 description 2
- VTGBZWHPJFMTKS-UHFFFAOYSA-N CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl Chemical compound CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl VTGBZWHPJFMTKS-UHFFFAOYSA-N 0.000 description 2
- RWJPSWDJRISNKF-UHFFFAOYSA-N C.C.CC.CCOCC Chemical compound C.C.CC.CCOCC RWJPSWDJRISNKF-UHFFFAOYSA-N 0.000 description 1
- LLHNGCPHCMJQIG-UHFFFAOYSA-N C.CC.CCOC Chemical compound C.CC.CCOC LLHNGCPHCMJQIG-UHFFFAOYSA-N 0.000 description 1
- JUWDLTVEBVWJKQ-UHFFFAOYSA-N C.CC.CCOCC Chemical compound C.CC.CCOCC JUWDLTVEBVWJKQ-UHFFFAOYSA-N 0.000 description 1
- CQFOHGXOJICVIO-UHFFFAOYSA-N C1=CC=C2CNCCC2=C1.O=[N+]([O-])C1=CC2=C(C=C1)CCNC2.O=[N+]([O-])C1=CC2=C(Cl)N=CC=C2C=C1.O=[N+]([O-])C1=CC2=CN=CC=C2C=C1.O=[N+]([O-])C1=CC2=C[N+]([O-])=CC=C2C=C1.[I-17].[I-18].[I-19].[I-20].[I-21] Chemical compound C1=CC=C2CNCCC2=C1.O=[N+]([O-])C1=CC2=C(C=C1)CCNC2.O=[N+]([O-])C1=CC2=C(Cl)N=CC=C2C=C1.O=[N+]([O-])C1=CC2=CN=CC=C2C=C1.O=[N+]([O-])C1=CC2=C[N+]([O-])=CC=C2C=C1.[I-17].[I-18].[I-19].[I-20].[I-21] CQFOHGXOJICVIO-UHFFFAOYSA-N 0.000 description 1
- HFEMALHVVXJIQI-UHFFFAOYSA-N C=CC1=C(C(=O)NC2=CC3=C(C=C2)N=C(C)C=C3N)C=CC=C1 Chemical compound C=CC1=C(C(=O)NC2=CC3=C(C=C2)N=C(C)C=C3N)C=CC=C1 HFEMALHVVXJIQI-UHFFFAOYSA-N 0.000 description 1
- AQHKEUBIXFGKBN-UHFFFAOYSA-N CC(=O)C1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl Chemical compound CC(=O)C1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl AQHKEUBIXFGKBN-UHFFFAOYSA-N 0.000 description 1
- OFCBXSSONYYCPR-UHFFFAOYSA-N CC(=O)OC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl Chemical compound CC(=O)OC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl OFCBXSSONYYCPR-UHFFFAOYSA-N 0.000 description 1
- LYZSOAXCKRTYLF-UHFFFAOYSA-N CC(=O)OCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1.Cl Chemical compound CC(=O)OCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1.Cl LYZSOAXCKRTYLF-UHFFFAOYSA-N 0.000 description 1
- BVESVAXWBDIEDL-UHFFFAOYSA-N CC(C)C1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC(C)C1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl BVESVAXWBDIEDL-UHFFFAOYSA-N 0.000 description 1
- PRPOAIOVUNRKBD-UHFFFAOYSA-N CC.CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C2)/C(N(C)C)=C\1.Cl Chemical compound CC.CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C2)/C(N(C)C)=C\1.Cl PRPOAIOVUNRKBD-UHFFFAOYSA-N 0.000 description 1
- OCGURXPOEFNVLB-UHFFFAOYSA-N CC.CC1=NC2=C(CC(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)CC2)C(N)=C1.Cl Chemical compound CC.CC1=NC2=C(CC(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)CC2)C(N)=C1.Cl OCGURXPOEFNVLB-UHFFFAOYSA-N 0.000 description 1
- MPTQZMIEKNWRMR-UHFFFAOYSA-N CC.CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(CC)\C=C/4N)C=CC=C2)C(Cl)=C1.Cl Chemical compound CC.CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(CC)\C=C/4N)C=CC=C2)C(Cl)=C1.Cl MPTQZMIEKNWRMR-UHFFFAOYSA-N 0.000 description 1
- ZTZIHLPGSQRIOX-UHFFFAOYSA-N CC.CCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C(C)=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC.CCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C(C)=C4)C=CC=C3)C=C2)C(N)=C1.Cl ZTZIHLPGSQRIOX-UHFFFAOYSA-N 0.000 description 1
- HFPSZUQFTQRZAK-UHFFFAOYSA-N CC1=CC(C)=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1.Cl Chemical compound CC1=CC(C)=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1.Cl HFPSZUQFTQRZAK-UHFFFAOYSA-N 0.000 description 1
- NJJYCHUUOLHVET-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(C4=CC=CC=C4)C=CC=C3)C=CC2=N1 Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(C4=CC=CC=C4)C=CC=C3)C=CC2=N1 NJJYCHUUOLHVET-UHFFFAOYSA-N 0.000 description 1
- OARLHLABDSCPNB-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CC4=CC=CC=C4)C=CC=C3)C=CC2=N1 Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CC4=CC=CC=C4)C=CC=C3)C=CC2=N1 OARLHLABDSCPNB-UHFFFAOYSA-N 0.000 description 1
- PEIHTOMPHVPEIY-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CCC4=CC=CC=C4)C=CC=C3)C=CC2=N1 Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CCC4=CC=CC=C4)C=CC=C3)C=CC2=N1 PEIHTOMPHVPEIY-UHFFFAOYSA-N 0.000 description 1
- GDSFRBOVQXWMPR-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl GDSFRBOVQXWMPR-UHFFFAOYSA-N 0.000 description 1
- CSTQSQIXYLPHPA-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl CSTQSQIXYLPHPA-UHFFFAOYSA-N 0.000 description 1
- MVOVJQHLQIQDFY-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl MVOVJQHLQIQDFY-UHFFFAOYSA-N 0.000 description 1
- ZNZXXSZVDVWVNA-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(CCCCCCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl ZNZXXSZVDVWVNA-UHFFFAOYSA-N 0.000 description 1
- RUKNNOJYHDNZAV-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(NC(=O)C4=CC=CC=C4)C=CC=C3)C=CC2=N1 Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(NC(=O)C4=CC=CC=C4)C=CC=C3)C=CC2=N1 RUKNNOJYHDNZAV-UHFFFAOYSA-N 0.000 description 1
- CASDXCVBZNHQHQ-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=C(OCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=C(OCC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl CASDXCVBZNHQHQ-UHFFFAOYSA-N 0.000 description 1
- SYCYQXDOCOBIEB-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC(C4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC(C4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl SYCYQXDOCOBIEB-UHFFFAOYSA-N 0.000 description 1
- MRDPOURVRTWSLY-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC(CC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC(CC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl MRDPOURVRTWSLY-UHFFFAOYSA-N 0.000 description 1
- ODZDRZHJDZKKNV-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC(CCC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC(CCC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl ODZDRZHJDZKKNV-UHFFFAOYSA-N 0.000 description 1
- SPROIWHKVSHPHU-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC(CCCC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC(CCCC4=CC=CC=C4)=CC=C3)C=CC2=N1.Cl SPROIWHKVSHPHU-UHFFFAOYSA-N 0.000 description 1
- SDFZNLYBELDZDG-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCCCOC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCCCOC3=CC=CC=C3)C=CC2=N1.Cl SDFZNLYBELDZDG-UHFFFAOYSA-N 0.000 description 1
- YRBZJPYFEPZFQW-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCCOC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCCOC3=CC=CC=C3)C=CC2=N1.Cl YRBZJPYFEPZFQW-UHFFFAOYSA-N 0.000 description 1
- PHQCHJTXHYNIJR-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCOC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCCOC3=CC=CC=C3)C=CC2=N1.Cl PHQCHJTXHYNIJR-UHFFFAOYSA-N 0.000 description 1
- WEXVQHRRMQUMSP-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCOC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCCOC3=CC=CC=C3)C=CC2=N1.Cl WEXVQHRRMQUMSP-UHFFFAOYSA-N 0.000 description 1
- HIOYRGIMWUCGDE-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCOC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3CCOC3=CC=CC=C3)C=CC2=N1.Cl HIOYRGIMWUCGDE-UHFFFAOYSA-N 0.000 description 1
- IDXZCNVSCPGYGN-UHFFFAOYSA-N CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(CO)C=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(CO)C=C3)C=CC2=N1.Cl IDXZCNVSCPGYGN-UHFFFAOYSA-N 0.000 description 1
- PSLQNZAZDQOTJW-FQEVSTJZSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)C3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)C3=CC=CC=C3)C=CC2=N1.Cl PSLQNZAZDQOTJW-FQEVSTJZSA-N 0.000 description 1
- GSRHKBQCEAMIEK-NRFANRHFSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CC3=CC=CC=C3)C=CC2=N1.Cl GSRHKBQCEAMIEK-NRFANRHFSA-N 0.000 description 1
- YRPSBPMCFSFCIN-QFIPXVFZSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CCC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CCC3=CC=CC=C3)C=CC2=N1.Cl YRPSBPMCFSFCIN-QFIPXVFZSA-N 0.000 description 1
- FXGOANSSKZBVLJ-QHCPKHFHSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CCCC3=CC=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3C(=O)CCCC3=CC=CC=C3)C=CC2=N1.Cl FXGOANSSKZBVLJ-QHCPKHFHSA-N 0.000 description 1
- ZCUDAZGJTOUODF-QHCPKHFHSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCCC3=CC=CC=C3)C=CC2=N1 Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCCC3=CC=CC=C3)C=CC2=N1 ZCUDAZGJTOUODF-QHCPKHFHSA-N 0.000 description 1
- QVCYWJQICBCOCW-QHCPKHFHSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl QVCYWJQICBCOCW-QHCPKHFHSA-N 0.000 description 1
- IMEBVCWYJNBELQ-QFIPXVFZSA-N CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@@H]3CCCN3CCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl IMEBVCWYJNBELQ-QFIPXVFZSA-N 0.000 description 1
- IMEBVCWYJNBELQ-JOCHJYFZSA-N CC1=CC(N)=C2C=C(NC(=O)[C@H]3CCCN3CCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl Chemical compound CC1=CC(N)=C2C=C(NC(=O)[C@H]3CCCN3CCOC3=CC=C(Cl)C=C3)C=CC2=N1.Cl.Cl IMEBVCWYJNBELQ-JOCHJYFZSA-N 0.000 description 1
- ROPXGSNDFUBQHF-UHFFFAOYSA-N CC1=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)=CC=C1 Chemical compound CC1=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)=CC=C1 ROPXGSNDFUBQHF-UHFFFAOYSA-N 0.000 description 1
- IHEWDSLCCFRZFU-UHFFFAOYSA-N CC1=CC=C(CCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl Chemical compound CC1=CC=C(CCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl IHEWDSLCCFRZFU-UHFFFAOYSA-N 0.000 description 1
- YCHFOIQKCJYSPV-UHFFFAOYSA-N CC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)C(Cl)=C1.Cl Chemical compound CC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)C(Cl)=C1.Cl YCHFOIQKCJYSPV-UHFFFAOYSA-N 0.000 description 1
- KWNJXLZXSTWZSE-UHFFFAOYSA-N CC1=CC=C(OCC2=C(C(=O)NC3=CC=C4/N=C(CO)\C=C(\N)C4=C3)C=CC=C2)C=C1.Cl Chemical compound CC1=CC=C(OCC2=C(C(=O)NC3=CC=C4/N=C(CO)\C=C(\N)C4=C3)C=CC=C2)C=C1.Cl KWNJXLZXSTWZSE-UHFFFAOYSA-N 0.000 description 1
- OAVBZAVCCFWUSH-UHFFFAOYSA-N CC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl Chemical compound CC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl OAVBZAVCCFWUSH-UHFFFAOYSA-N 0.000 description 1
- KAQBAOOTAUYKAA-UHFFFAOYSA-N CC1=CC=C(OCCCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl Chemical compound CC1=CC=C(OCCCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl KAQBAOOTAUYKAA-UHFFFAOYSA-N 0.000 description 1
- DKDGPIKKYBKKQQ-UHFFFAOYSA-N CC1=CC=C2C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl Chemical compound CC1=CC=C2C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=CC2=N1.Cl DKDGPIKKYBKKQQ-UHFFFAOYSA-N 0.000 description 1
- OKDOCDUEZGMGQH-UHFFFAOYSA-N CC1=C\C(N)=C2\C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C\C2=N\1.Cl Chemical compound CC1=C\C(N)=C2\C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C\C2=N\1.Cl OKDOCDUEZGMGQH-UHFFFAOYSA-N 0.000 description 1
- PMMUSRSOKNLZDS-UHFFFAOYSA-N CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(C(F)(F)F)C=C3)C=C\C2=N\1.Cl Chemical compound CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(C(F)(F)F)C=C3)C=C\C2=N\1.Cl PMMUSRSOKNLZDS-UHFFFAOYSA-N 0.000 description 1
- BUMAAVJDIPVXNH-UHFFFAOYSA-N CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(Cl)C=C3)C=C\C2=N\1.Cl Chemical compound CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(Cl)C=C3)C=C\C2=N\1.Cl BUMAAVJDIPVXNH-UHFFFAOYSA-N 0.000 description 1
- QIHCYLMVUVGDCQ-UHFFFAOYSA-N CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=CC([N+](=O)[O-])=C3)C=C\C2=N\1.Cl Chemical compound CC1=C\C(N)=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=CC([N+](=O)[O-])=C3)C=C\C2=N\1.Cl QIHCYLMVUVGDCQ-UHFFFAOYSA-N 0.000 description 1
- MMDYFXPOSJWRFC-UHFFFAOYSA-N CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(F)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl Chemical compound CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(F)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl MMDYFXPOSJWRFC-UHFFFAOYSA-N 0.000 description 1
- UPJOJZCQJRNBTC-UHFFFAOYSA-N CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(O)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl Chemical compound CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(O)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl UPJOJZCQJRNBTC-UHFFFAOYSA-N 0.000 description 1
- FIYXJQCJWBLXJW-UHFFFAOYSA-N CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(S(C)(=O)=O)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl Chemical compound CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=C(S(C)(=O)=O)C=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl FIYXJQCJWBLXJW-UHFFFAOYSA-N 0.000 description 1
- ZXVBNLOWQFGSTE-UHFFFAOYSA-N CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC(Cl)=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl Chemical compound CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC(Cl)=C4)C=CC=C3)C=C2)/C(N)=C\1.Cl ZXVBNLOWQFGSTE-UHFFFAOYSA-N 0.000 description 1
- DKCHWYNBHCMRKN-UHFFFAOYSA-N CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4[N+](=O)[O-])C=CC=C3)C=C2)/C(N)=C\1.Cl Chemical compound CC1=N/C2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4[N+](=O)[O-])C=CC=C3)C=C2)/C(N)=C\1.Cl DKCHWYNBHCMRKN-UHFFFAOYSA-N 0.000 description 1
- CHNGMZDFOLPHBK-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=C(Cl)C=C(Cl)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=C(Cl)C=C(Cl)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl CHNGMZDFOLPHBK-UHFFFAOYSA-N 0.000 description 1
- IWEDYRWXTAWCAS-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=C(Cl)C=CC=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=C(Cl)C=CC=C4)C=CC=C3)C=C2/C(N)=C\1.Cl IWEDYRWXTAWCAS-UHFFFAOYSA-N 0.000 description 1
- SYIMEDFJFQLCNJ-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC(Cl)=C(Cl)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC(Cl)=C(Cl)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl SYIMEDFJFQLCNJ-UHFFFAOYSA-N 0.000 description 1
- MZMPSIMHEFFOPG-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C#N)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C#N)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl MZMPSIMHEFFOPG-UHFFFAOYSA-N 0.000 description 1
- RZNSGVHLDRKUQL-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C(C)(C)C)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C(C)(C)C)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl RZNSGVHLDRKUQL-UHFFFAOYSA-N 0.000 description 1
- BPVRYPMFVQOQSB-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C5=CC=CC=C5)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(C5=CC=CC=C5)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl BPVRYPMFVQOQSB-UHFFFAOYSA-N 0.000 description 1
- TYEPAHFCKGWFKS-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(N(C)C)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(N(C)C)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl.Cl TYEPAHFCKGWFKS-UHFFFAOYSA-N 0.000 description 1
- PFIFPQFMXOXEOF-UHFFFAOYSA-N CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(N)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl.Cl Chemical compound CC1=N/C2=CC=C(NC(=O)C3=C(COC4=CC=C(N)C=C4)C=CC=C3)C=C2/C(N)=C\1.Cl.Cl PFIFPQFMXOXEOF-UHFFFAOYSA-N 0.000 description 1
- IVPXXHLEWJIMGZ-VAWYXSNFSA-N CC1=NC2=C(C=C(NC(=O)C3=C(/C=C/C4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(/C=C/C4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 IVPXXHLEWJIMGZ-VAWYXSNFSA-N 0.000 description 1
- IVPXXHLEWJIMGZ-QXMHVHEDSA-N CC1=NC2=C(C=C(NC(=O)C3=C(/C=C\C4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(/C=C\C4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 IVPXXHLEWJIMGZ-QXMHVHEDSA-N 0.000 description 1
- FKCBRPSWYQIABA-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(C#N)C=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(C#N)C=CC=C3)C=C2)C(N)=C1 FKCBRPSWYQIABA-UHFFFAOYSA-N 0.000 description 1
- CRTOXKNYEGVSNP-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(CCC4CCCCC4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(CCC4CCCCC4)C=CC=C3)C=C2)C(N)=C1.Cl CRTOXKNYEGVSNP-UHFFFAOYSA-N 0.000 description 1
- MOZQBRBLRNOHEX-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(CCCCCCCOC4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(CCCCCCCOC4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1.Cl MOZQBRBLRNOHEX-UHFFFAOYSA-N 0.000 description 1
- BEFVEQGXGVJGQU-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(CN(C(=O)OC(C)(C)C)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(CN(C(=O)OC(C)(C)C)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl BEFVEQGXGVJGQU-UHFFFAOYSA-N 0.000 description 1
- QUPAGVOVWOHWPG-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(CNC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl.Cl Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(CNC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl.Cl QUPAGVOVWOHWPG-UHFFFAOYSA-N 0.000 description 1
- DHSJUCNREVVDSF-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC5=C(C=CC=C5)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC5=C(C=CC=C5)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl DHSJUCNREVVDSF-UHFFFAOYSA-N 0.000 description 1
- QGDXGBYLVHPULC-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(I)C=C4)C=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(I)C=C4)C=CC=C3)C=C2)C(N)=C1 QGDXGBYLVHPULC-UHFFFAOYSA-N 0.000 description 1
- RNJKRHUGEVULBU-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=C(COCC4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=C(COCC4=CC=CC=C4)C=CC=C3)C=C2)C(N)=C1 RNJKRHUGEVULBU-UHFFFAOYSA-N 0.000 description 1
- GNKMGESJOVRMEO-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=CC=C(CC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=CC=C(CC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 GNKMGESJOVRMEO-UHFFFAOYSA-N 0.000 description 1
- RIKDBGARHGQOFX-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=CC=C(CCC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=CC=C(CCC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 RIKDBGARHGQOFX-UHFFFAOYSA-N 0.000 description 1
- WTEWXYMFZNYDDT-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=CC=C(CCCC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=CC=C(CCCC4=CC=CC=C4)C=C3)C=C2)C(N)=C1 WTEWXYMFZNYDDT-UHFFFAOYSA-N 0.000 description 1
- SBMGFSCRPGXVOV-UHFFFAOYSA-N CC1=NC2=C(C=C(NC(=O)C3=CC=CC=C3)C=C2)C(N)=C1 Chemical compound CC1=NC2=C(C=C(NC(=O)C3=CC=CC=C3)C=C2)C(N)=C1 SBMGFSCRPGXVOV-UHFFFAOYSA-N 0.000 description 1
- NQHCFXVEBOGJQZ-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(CCCOC4=C(Cl)C=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(CCCOC4=C(Cl)C=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl NQHCFXVEBOGJQZ-UHFFFAOYSA-N 0.000 description 1
- IFGIHSHIFPSKSH-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(CCOC4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(CCOC4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl IFGIHSHIFPSKSH-UHFFFAOYSA-N 0.000 description 1
- VQLORGUZNLOKHI-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(CN(C)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(CN(C)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl.Cl VQLORGUZNLOKHI-UHFFFAOYSA-N 0.000 description 1
- PUAYIXQMKNNCMP-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(C#N)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(C#N)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl PUAYIXQMKNNCMP-UHFFFAOYSA-N 0.000 description 1
- JWWOTBPQPSGHII-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(C(F)(F)F)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC(C(F)(F)F)=CC=C4)C=CC=C3)C=C2C(N)=C1.Cl JWWOTBPQPSGHII-UHFFFAOYSA-N 0.000 description 1
- PMXREEBJURXBLS-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)CCCC5)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)CCCC5)C=CC=C3)C=C2C(N)=C1.Cl PMXREEBJURXBLS-UHFFFAOYSA-N 0.000 description 1
- DIMXTSWFXGNJGR-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)OC=C5)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)OC=C5)C=CC=C3)C=C2C(N)=C1.Cl DIMXTSWFXGNJGR-UHFFFAOYSA-N 0.000 description 1
- DZSCTOPGDSVUGN-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)OCC5)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC5=C(C=C4)OCC5)C=CC=C3)C=C2C(N)=C1.Cl DZSCTOPGDSVUGN-UHFFFAOYSA-N 0.000 description 1
- NYVHPWQPFYEOAS-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Br)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Br)C=C4)C=CC=C3)C=C2C(N)=C1.Cl NYVHPWQPFYEOAS-UHFFFAOYSA-N 0.000 description 1
- WWIICPXEUDPLRX-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(C(=O)O)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(C(=O)O)C=C4)C=CC=C3)C=C2C(N)=C1.Cl WWIICPXEUDPLRX-UHFFFAOYSA-N 0.000 description 1
- MKUOGCKPJLDTPI-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(C(C)C)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(C(C)C)C=C4)C=CC=C3)C=C2C(N)=C1.Cl MKUOGCKPJLDTPI-UHFFFAOYSA-N 0.000 description 1
- ZELJDOVYCAHKBK-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CO3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CO3)C=C2C(N)=C1.Cl ZELJDOVYCAHKBK-UHFFFAOYSA-N 0.000 description 1
- YRRAITPLWWEDFH-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CS3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CS3)C=C2C(N)=C1.Cl YRRAITPLWWEDFH-UHFFFAOYSA-N 0.000 description 1
- AOZFBYYXPYOFAQ-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)OC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)OC=C3)C=C2C(N)=C1.Cl AOZFBYYXPYOFAQ-UHFFFAOYSA-N 0.000 description 1
- BTEKRXWTXJETEC-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)OC=N3)C=C2C(N)=C1 Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)OC=N3)C=C2C(N)=C1 BTEKRXWTXJETEC-UHFFFAOYSA-N 0.000 description 1
- DIILCWCBSSLZPN-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=CC=C4)CCCC3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(COC4=CC=CC=C4)CCCC3)C=C2C(N)=C1.Cl DIILCWCBSSLZPN-UHFFFAOYSA-N 0.000 description 1
- OYPNDPMJNZCLFD-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(CS(=O)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(CS(=O)C4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl OYPNDPMJNZCLFD-UHFFFAOYSA-N 0.000 description 1
- XZCQIIHTDWYONH-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=C(CSC4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=C(CSC4=CC=C(Cl)C=C4)C=CC=C3)C=C2C(N)=C1.Cl XZCQIIHTDWYONH-UHFFFAOYSA-N 0.000 description 1
- GJKXBYRIRNMMRN-UHFFFAOYSA-N CC1=NC2=CC=C(NC(=O)C3=CC=CN3CCOC3=CC=C(Cl)C=C3)C=C2C(N)=C1.Cl Chemical compound CC1=NC2=CC=C(NC(=O)C3=CC=CN3CCOC3=CC=C(Cl)C=C3)C=C2C(N)=C1.Cl GJKXBYRIRNMMRN-UHFFFAOYSA-N 0.000 description 1
- POTNMMSRISAGBU-UHFFFAOYSA-N CCC1=CC(Cl)=C(OCC2=C(C(=O)NC3=CC4=C(N)C=C(C)N=C4C=C3)C=CC=C2)C=C1.Cl Chemical compound CCC1=CC(Cl)=C(OCC2=C(C(=O)NC3=CC4=C(N)C=C(C)N=C4C=C3)C=CC=C2)C=C1.Cl POTNMMSRISAGBU-UHFFFAOYSA-N 0.000 description 1
- DNYGSLORMFQVKT-UHFFFAOYSA-N CCC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=C(Cl)C=C(Cl)C=C3)C=CC2=N1.Cl Chemical compound CCC1=CC(N)=C2C=C(NC(=O)C3=CC=CC=C3COC3=C(Cl)C=C(Cl)C=C3)C=CC2=N1.Cl DNYGSLORMFQVKT-UHFFFAOYSA-N 0.000 description 1
- XEJQVPDZBNCIAX-UHFFFAOYSA-N CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(CC)C=C4N)C=CC=C2)C=C1.Cl Chemical compound CCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(CC)C=C4N)C=CC=C2)C=C1.Cl XEJQVPDZBNCIAX-UHFFFAOYSA-N 0.000 description 1
- DERSUXKUZYTYFC-UHFFFAOYSA-N CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C/N=C\3C=C2)C=C1.Cl Chemical compound CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C/N=C\3C=C2)C=C1.Cl DERSUXKUZYTYFC-UHFFFAOYSA-N 0.000 description 1
- YKCHUWVQEWMLGS-UHFFFAOYSA-N CCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl YKCHUWVQEWMLGS-UHFFFAOYSA-N 0.000 description 1
- SIGCHXAGKITIOK-UHFFFAOYSA-N CCCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)C=C1.Cl Chemical compound CCCC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=CC=C2)C=C1.Cl SIGCHXAGKITIOK-UHFFFAOYSA-N 0.000 description 1
- PXUVWPAZAHWNHO-UHFFFAOYSA-N CCCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl Chemical compound CCCC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C2)C(N)=C1.Cl PXUVWPAZAHWNHO-UHFFFAOYSA-N 0.000 description 1
- FCRBAZGTQXJKHD-UHFFFAOYSA-N CNC1=CC(C)=NC2=CC=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C21.Cl Chemical compound CNC1=CC(C)=NC2=CC=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C21.Cl FCRBAZGTQXJKHD-UHFFFAOYSA-N 0.000 description 1
- OFARWIVODCZENY-UHFFFAOYSA-N CNC1=NC2=C(C=C1)C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 Chemical compound CNC1=NC2=C(C=C1)C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 OFARWIVODCZENY-UHFFFAOYSA-N 0.000 description 1
- FAZLIYJUNVFKOA-UHFFFAOYSA-N COC(=O)C1=CC=C(OCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl Chemical compound COC(=O)C1=CC=C(OCC2=C(C(=O)NC3=CC=C4N=C(C)C=C(N)C4=C3)C=CC=C2)C=C1.Cl FAZLIYJUNVFKOA-UHFFFAOYSA-N 0.000 description 1
- PDTJTTXJHKQXPK-UHFFFAOYSA-N COC1=C(OC)C=C(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)C=C1.Cl Chemical compound COC1=C(OC)C=C(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)C=C1.Cl PDTJTTXJHKQXPK-UHFFFAOYSA-N 0.000 description 1
- TWSZANACVGSRHJ-UHFFFAOYSA-N COC1=CC(OC)=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)=C1.Cl Chemical compound COC1=CC(OC)=CC(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)=C1.Cl TWSZANACVGSRHJ-UHFFFAOYSA-N 0.000 description 1
- ZDRUFWGHGMSZQN-UHFFFAOYSA-N COC1=CC=C(CCC2=C(C(=O)NC3=CC4=C(N)C=C(C)N=C4C=C3)C=CC=C2)C=C1.Cl Chemical compound COC1=CC=C(CCC2=C(C(=O)NC3=CC4=C(N)C=C(C)N=C4C=C3)C=CC=C2)C=C1.Cl ZDRUFWGHGMSZQN-UHFFFAOYSA-N 0.000 description 1
- DZRGTUXVPIVOBL-UHFFFAOYSA-N COC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl Chemical compound COC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)/C=C(C)/N=C\3C=C2)C=C1.Cl DZRGTUXVPIVOBL-UHFFFAOYSA-N 0.000 description 1
- QPDMIIYUYIYVAY-UHFFFAOYSA-N COC1=CC=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1.Cl Chemical compound COC1=CC=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1.Cl QPDMIIYUYIYVAY-UHFFFAOYSA-N 0.000 description 1
- ODAUXTRMPDHLAG-UHFFFAOYSA-N COC1=CC=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1OC.Cl Chemical compound COC1=CC=CC(OCC2=C(C(=O)NC3=CC=C4/N=C(C)\C=C(\N)C4=C3)C=CC=C2)=C1OC.Cl ODAUXTRMPDHLAG-UHFFFAOYSA-N 0.000 description 1
- SZUNTNRURPNUJO-UHFFFAOYSA-N COC1=CC=CC=C1OCC1=C(C(=O)NC2=CC3=C(C=C2)/N=C(C)\C=C/3N)C=CC=C1.Cl Chemical compound COC1=CC=CC=C1OCC1=C(C(=O)NC2=CC3=C(C=C2)/N=C(C)\C=C/3N)C=CC=C1.Cl SZUNTNRURPNUJO-UHFFFAOYSA-N 0.000 description 1
- GBHKRQXMYBZZCL-UHFFFAOYSA-N COCC1=C(C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=CC=C1.Cl Chemical compound COCC1=C(C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=CC=C1.Cl GBHKRQXMYBZZCL-UHFFFAOYSA-N 0.000 description 1
- OHPFSTXIRAJWCO-UHFFFAOYSA-N COCOC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl Chemical compound COCOC1=CC=C(OCC2=C(C(=O)NC3=CC4=C(C=C3)/N=C(C)\C=C/4N)C=CC=C2)C=C1.Cl OHPFSTXIRAJWCO-UHFFFAOYSA-N 0.000 description 1
- QDZBHRNYULKIAT-UHFFFAOYSA-N COCOCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)\C=C/N=C\3C=C2)C=C1.Cl Chemical compound COCOCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)\C=C/N=C\3C=C2)C=C1.Cl QDZBHRNYULKIAT-UHFFFAOYSA-N 0.000 description 1
- WKTVHFVLPCCKRO-UHFFFAOYSA-N CSC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C2)N1.Cl Chemical compound CSC1=NC2=C(C=C(NC(=O)C3=C(COC4=CC=CC=C4)C=CC=C3)C=C2)N1.Cl WKTVHFVLPCCKRO-UHFFFAOYSA-N 0.000 description 1
- YTSIAFYETCWQIK-UHFFFAOYSA-N Cc(cc(c1c2)N)nc1ccc2NC(c1cccc(CCCc2ccccc2)c1)=C Chemical compound Cc(cc(c1c2)N)nc1ccc2NC(c1cccc(CCCc2ccccc2)c1)=C YTSIAFYETCWQIK-UHFFFAOYSA-N 0.000 description 1
- UOIUZMRZTOWBPP-CMDGGOBGSA-N Cc1cc(N)c(cc(cc2)NC(c3c(C/C=C/c(cc4)ccc4-c4ccccc4)cccc3)=C)c2n1 Chemical compound Cc1cc(N)c(cc(cc2)NC(c3c(C/C=C/c(cc4)ccc4-c4ccccc4)cccc3)=C)c2n1 UOIUZMRZTOWBPP-CMDGGOBGSA-N 0.000 description 1
- FMMSMGGWEQYSPC-VWLOTQADSA-N Cc1nc(ccc(NC([C@H](CCC2)N2C(CCCc2ccccc2)=C)=[ClH])c2)c2c(N)c1 Chemical compound Cc1nc(ccc(NC([C@H](CCC2)N2C(CCCc2ccccc2)=C)=[ClH])c2)c2c(N)c1 FMMSMGGWEQYSPC-VWLOTQADSA-N 0.000 description 1
- VORPODIQNSZUAW-MHZLTWQESA-N Cc1nc(ccc(NC([C@H]2N(CC/C=C/c(cc3)ccc3[I-])CCC2)=C=C)c2)c2c(N)c1 Chemical compound Cc1nc(ccc(NC([C@H]2N(CC/C=C/c(cc3)ccc3[I-])CCC2)=C=C)c2)c2c(N)c1 VORPODIQNSZUAW-MHZLTWQESA-N 0.000 description 1
- XBTBXCJVDZOUNH-UHFFFAOYSA-N Cc1nc(ccc(NC(c2c(Cc3ccccc3)cccc2)=[ClH])c2)c2c(N)c1 Chemical compound Cc1nc(ccc(NC(c2c(Cc3ccccc3)cccc2)=[ClH])c2)c2c(N)c1 XBTBXCJVDZOUNH-UHFFFAOYSA-N 0.000 description 1
- YDUMGSJWKZMNSC-UHFFFAOYSA-N Cl.N/C1=C2\CCCC\C2=N\C2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C21 Chemical compound Cl.N/C1=C2\CCCC\C2=N\C2=CC=C(NC(=O)C3=C(COC4=CC=C(Cl)C=C4)C=CC=C3)C=C21 YDUMGSJWKZMNSC-UHFFFAOYSA-N 0.000 description 1
- JJXYWNGENOBXTL-UHFFFAOYSA-N Cl.NC1=C2C=C(NC(=O)C3=CC=CC=C3COC3=CC=CC=C3)C=CC2=CC=C1 Chemical compound Cl.NC1=C2C=C(NC(=O)C3=CC=CC=C3COC3=CC=CC=C3)C=CC2=CC=C1 JJXYWNGENOBXTL-UHFFFAOYSA-N 0.000 description 1
- QJXYUUXRTUJQLW-UHFFFAOYSA-N Cl.NC1=C2CCCC2=NC2=C1C=C(NC(=O)C1=C(COC3=CC=C(Cl)C=C3)C=CC=C1)C=C2 Chemical compound Cl.NC1=C2CCCC2=NC2=C1C=C(NC(=O)C1=C(COC3=CC=C(Cl)C=C3)C=CC=C1)C=C2 QJXYUUXRTUJQLW-UHFFFAOYSA-N 0.000 description 1
- LGBRWRDQRLXJGW-UHFFFAOYSA-N Cl.NC1=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(Cl)C=C3)C=C\C2=N\C=C\1 Chemical compound Cl.NC1=C2\C=C(NC(=O)C3=CC=CC=C3COC3=CC=C(Cl)C=C3)C=C\C2=N\C=C\1 LGBRWRDQRLXJGW-UHFFFAOYSA-N 0.000 description 1
- HRUKLSGJSTXOQB-UHFFFAOYSA-N Cl.NC1=CC=C(NC(=O)C2=C(COC3=CC=CC=C3)C=CC=C2)C=C1 Chemical compound Cl.NC1=CC=C(NC(=O)C2=C(COC3=CC=CC=C3)C=CC=C2)C=C1 HRUKLSGJSTXOQB-UHFFFAOYSA-N 0.000 description 1
- XSDNRYTVXVAEPP-UHFFFAOYSA-N Cl.NC1=NC2=C(C=C1)C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 Chemical compound Cl.NC1=NC2=C(C=C1)C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 XSDNRYTVXVAEPP-UHFFFAOYSA-N 0.000 description 1
- AVRWAWIOJQBFAB-UHFFFAOYSA-N Cl.NC1=NC=CC2=C1C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 Chemical compound Cl.NC1=NC=CC2=C1C=C(NC(=O)C1=C(COC3=CC=CC=C3)C=CC=C1)C=C2 AVRWAWIOJQBFAB-UHFFFAOYSA-N 0.000 description 1
- JFDUOFGMZJAIJX-UHFFFAOYSA-N Cl.O=C(NC1=CC=C2N=CC=NC2=C1)C1=C(COC2=CC=CC=C2)C=CC=C1 Chemical compound Cl.O=C(NC1=CC=C2N=CC=NC2=C1)C1=C(COC2=CC=CC=C2)C=CC=C1 JFDUOFGMZJAIJX-UHFFFAOYSA-N 0.000 description 1
- WESSQBZVFOIAQP-UHFFFAOYSA-N NC1=C2C=C([N+](=O)[O-])C=CC2=NC=C1Br.NC1=C2C=CC=CC2=NC=C1.NC1=C2C=CC=CC2=NC=C1Br.NC1=CC2=C(N)C=CN=C2C=C1.O=[N+]([O-])C1=C2C=CC=CC2=[N+]([O-])C=C1.[I-12].[I-13].[I-14].[I-15].[I-16] Chemical compound NC1=C2C=C([N+](=O)[O-])C=CC2=NC=C1Br.NC1=C2C=CC=CC2=NC=C1.NC1=C2C=CC=CC2=NC=C1Br.NC1=CC2=C(N)C=CN=C2C=C1.O=[N+]([O-])C1=C2C=CC=CC2=[N+]([O-])C=C1.[I-12].[I-13].[I-14].[I-15].[I-16] WESSQBZVFOIAQP-UHFFFAOYSA-N 0.000 description 1
- FXPPYYWULVGUPK-UHFFFAOYSA-N NC1=C2C=C([Y])C=CC2=NC2=C1CCCC2.O=C1CCCCC1.[C-]#[N+]C1=C(N)C=CC([Y])=C1.[I-22].[I-23].[I-24] Chemical compound NC1=C2C=C([Y])C=CC2=NC2=C1CCCC2.O=C1CCCCC1.[C-]#[N+]C1=C(N)C=CC([Y])=C1.[I-22].[I-23].[I-24] FXPPYYWULVGUPK-UHFFFAOYSA-N 0.000 description 1
- ZBOJGHLNEDKHAU-UHFFFAOYSA-N [H]C(C1=C(C(=O)NC2=CC3=C(C=C2)N=C(C)C=C3N)C=CC=C1)=C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound [H]C(C1=C(C(=O)NC2=CC3=C(C=C2)N=C(C)C=C3N)C=CC=C1)=C(C1=CC=CC=C1)C1=CC=CC=C1 ZBOJGHLNEDKHAU-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N c1cc2cccnc2cc1 Chemical compound c1cc2cccnc2cc1 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/141,866 US6903094B2 (en) | 1998-03-26 | 2002-05-10 | Amide derivatives and nociceptin antagonists |
US11/145,169 US20060030565A1 (en) | 1998-03-26 | 2005-06-06 | Amide derivatives and nociceptin antagonists |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10-100029 | 1998-03-26 | ||
JP10002998 | 1998-03-26 | ||
PCT/JP1999/001462 WO1999048492A1 (fr) | 1998-03-26 | 1999-03-23 | Derives d'amide et antagonistes de nociceptine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/001462 A-371-Of-International WO1999048492A1 (fr) | 1998-03-26 | 1999-03-23 | Derives d'amide et antagonistes de nociceptine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/141,866 Division US6903094B2 (en) | 1998-03-26 | 2002-05-10 | Amide derivatives and nociceptin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US6410561B1 true US6410561B1 (en) | 2002-06-25 |
Family
ID=14263120
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/646,781 Expired - Fee Related US6410561B1 (en) | 1998-03-26 | 1999-03-23 | Amide derivatives and nociceptin antagonists |
US10/141,866 Expired - Fee Related US6903094B2 (en) | 1998-03-26 | 2002-05-10 | Amide derivatives and nociceptin antagonists |
US11/145,169 Abandoned US20060030565A1 (en) | 1998-03-26 | 2005-06-06 | Amide derivatives and nociceptin antagonists |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/141,866 Expired - Fee Related US6903094B2 (en) | 1998-03-26 | 2002-05-10 | Amide derivatives and nociceptin antagonists |
US11/145,169 Abandoned US20060030565A1 (en) | 1998-03-26 | 2005-06-06 | Amide derivatives and nociceptin antagonists |
Country Status (21)
Country | Link |
---|---|
US (3) | US6410561B1 (zh) |
EP (1) | EP1072263A4 (zh) |
KR (1) | KR20010042161A (zh) |
CN (1) | CN1301154A (zh) |
AR (1) | AR018168A1 (zh) |
AU (1) | AU754716B2 (zh) |
BR (1) | BR9909666A (zh) |
CA (1) | CA2325638A1 (zh) |
CO (1) | CO5080780A1 (zh) |
FI (1) | FI20002103A (zh) |
HU (1) | HUP0101275A3 (zh) |
ID (1) | ID26099A (zh) |
IL (1) | IL138573A0 (zh) |
NO (1) | NO20004778L (zh) |
NZ (1) | NZ507760A (zh) |
RU (1) | RU2202344C2 (zh) |
SK (1) | SK14272000A3 (zh) |
TR (1) | TR200003598T2 (zh) |
TW (1) | TW487571B (zh) |
WO (1) | WO1999048492A1 (zh) |
ZA (1) | ZA200005881B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092513A1 (en) * | 2002-08-07 | 2004-05-13 | Aventis Pharma Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
US20050026942A1 (en) * | 2000-09-15 | 2005-02-03 | Anormed | Chemokine receptor binding heterocyclic compounds |
US20050026915A1 (en) * | 2001-11-27 | 2005-02-03 | Devita Robert J. | 2-Aminoquinoline compounds |
US20050119308A1 (en) * | 2002-03-29 | 2005-06-02 | Koji Teshima | Remedy for sleep disturbance |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20070287751A1 (en) * | 2004-03-12 | 2007-12-13 | De La Torre Marta G | Opioid Receptor Antagonists |
US7312044B2 (en) | 2003-03-07 | 2007-12-25 | The Trustees Of Columbia University In The City Of New York | Type 1 ryanodine receptor-based methods |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US20090176838A1 (en) * | 2006-01-30 | 2009-07-09 | Purdue Pharma L.P. | Cyclourea Compounds as Calcium Channel Blockers |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US8722731B2 (en) | 2010-06-07 | 2014-05-13 | Novomedix, Llc | Furanyl compounds and the use thereof |
US8895606B2 (en) | 2010-08-24 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
WO2019020248A1 (de) * | 2017-07-24 | 2019-01-31 | Beiersdorf Ag | Verwendung von n-(4-amino-2-methylchinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamid zur herstellung von kosmetischen oder dermatologischen zubereitungen zur behandlung und/oder prophylaxe der symptome der intrinsischen und/oder extrinsischen hautalterung sowie zur behandlung und prophylaxe der schädlichen auswirkungen ultravioletter strahlung auf die haut |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2369695A1 (en) * | 1999-04-09 | 2000-10-19 | Manabu Itoh | Agent for treating neuropathic pain |
WO2001039775A1 (en) | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Benzimidazole compounds having nociceptin receptor affinity |
WO2001039767A1 (en) | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Tertiary amino compounds having opioid receptor affinity |
DE60033071T2 (de) | 1999-12-06 | 2007-08-23 | Euro-Celtique S.A. | Triazospiroverbindungen mit nociceptin-rezeptoraffinität |
DE19963175A1 (de) * | 1999-12-27 | 2001-07-12 | Gruenenthal Gmbh | Verwendung von substituierten 4-Amino-1-phenylbutan-2-ol-Verbindungen als Arzneimittel |
AU2001244688A1 (en) * | 2000-03-31 | 2001-10-08 | Nippon Shinyaku Co. Ltd. | Heterocycle derivatives and drugs |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
WO2002026714A1 (fr) * | 2000-09-27 | 2002-04-04 | Takeda Chemical Industries, Ltd. | Composes spiraniques |
SE0004054D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
WO2002040019A1 (fr) | 2000-11-15 | 2002-05-23 | Banyu Pharmaceutical Co.,Ltd. | Derives benzimidazoles |
AU2002218535A1 (en) * | 2000-12-12 | 2002-06-24 | Japan Tobacco Inc. | Pharmaceutical composition containing an active with a hemolytic action and a surfactant |
RU2003130752A (ru) * | 2001-03-19 | 2005-03-10 | Ниппон Синяку Ко., Лтд. (Jp) | Противозудные средства |
MXPA03009602A (es) | 2001-04-18 | 2004-04-02 | Euro Celtique Sa | Analogos de nociceptina. |
HUP0401333A3 (en) | 2001-04-18 | 2004-11-29 | Euro Celtique Sa | Spiropyrazole compounds and pharmaceutical compositions containing them |
ES2316559T3 (es) | 2001-04-18 | 2009-04-16 | Euro-Celtique S.A. | Compuestos espiroindeno y espiroindano. |
EP1918279A3 (en) | 2001-04-18 | 2008-07-16 | Euro-Celtique S.A. | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (orl1) ligands for the treatment of pain |
DK1975164T3 (da) | 2001-04-18 | 2010-05-25 | Euro Celtique Sa | Octahydrobenzimidazolon-forbindelser som analgetika |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
US7049287B2 (en) | 2001-10-09 | 2006-05-23 | Synvax, Inc. | Nociceptin-based analgesics |
US7235558B2 (en) * | 2002-06-06 | 2007-06-26 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the GPIb—vWF interaction, their preparation and use |
EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
AU2004241213B2 (en) | 2003-05-21 | 2009-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminoquinoline derivative |
US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
AR046276A1 (es) | 2003-10-07 | 2005-11-30 | Renovis Inc | Derivados de amida como ligandos de canales ionicos y composiciones farmaceuticas y metodos que los utilizan. |
JP2007509059A (ja) | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
EP1568698A1 (en) * | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
WO2005121255A1 (ja) | 2004-06-09 | 2005-12-22 | Kaneka Corporation | 硬化性組成物 |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
WO2008023333A2 (en) * | 2006-08-22 | 2008-02-28 | Ranbaxy Laboratories Limited | Process for the preparation of 4-(isobutylamino)-3-amino-quinoline |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
WO2009129301A2 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | Oral pharmaceutical compositions in a molecular solid dispersion |
PT2326651E (pt) | 2008-07-30 | 2014-02-12 | Purdue Pharma Lp | Análogos de buprenorfina |
EP2483254B1 (en) | 2009-09-29 | 2014-08-13 | Glaxo Group Limited | Novel compounds |
DK2619212T3 (en) | 2010-09-21 | 2016-03-21 | Purdue Pharma Lp | BUPRENORPHINANALOGER AS opioid receptor agonists and / or antagonists |
AU2012324012A1 (en) | 2011-12-08 | 2013-06-27 | Purdue Pharma L.P. | Quaternized buprenorphine analogs |
TWI622578B (zh) | 2011-12-21 | 2018-05-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
US20150210646A1 (en) | 2012-05-11 | 2015-07-30 | Purdue Pharma L.P. | Benzomorphan compounds as opioid receptors modulators |
BR112015004192B1 (pt) | 2012-08-28 | 2021-02-09 | Janssen Sciences Ireland Uc | sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b |
JP6400592B2 (ja) | 2012-11-09 | 2018-10-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | ベンゾモルファン類似体およびその使用 |
WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EP3357906B1 (en) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
CN105980378B (zh) | 2014-02-06 | 2019-09-27 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
EA201691728A1 (ru) | 2014-02-25 | 2017-02-28 | Ачиллион Фармасьютикалс, Инк. | Соединения с эфирными группами для лечения опосредованных комплементом нарушений |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
US9975854B2 (en) | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
WO2016003886A1 (en) * | 2014-07-02 | 2016-01-07 | Lam Therapeutics, Inc. | 4-aminoquinoline compositions and methods for using same |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CN105461623A (zh) * | 2015-12-29 | 2016-04-06 | 江苏理工学院 | 4-氨基-6-硝基-3-溴喹啉合成方法 |
SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
KR20210057086A (ko) | 2018-09-06 | 2021-05-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | 다니코판의 형태체 형태 |
WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
CN112996497A (zh) | 2018-09-25 | 2021-06-18 | 艾其林医药公司 | 补体因子d抑制剂的形态形式 |
MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
KR20220044753A (ko) * | 2019-07-25 | 2022-04-11 | 큐라데브 파마 프라이버트 리미티드 | 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5473784A (en) | 1977-11-07 | 1979-06-13 | Leo Pharm Prod Ltd | Substituted quinolylguanidine derivatives and their manufacture and use |
JPS59210084A (ja) | 1983-04-06 | 1984-11-28 | キエシ・フアルマチエウチチ・エツセ・ピ・ア | 抗炎症作用を有する化合物、その製法およびそれを有効成分とする医薬 |
JPS62503030A (ja) | 1985-05-07 | 1987-12-03 | アルカロイダ ベギエスゼテイ ギヤル | トリアゾリルキノリン誘導体 |
JPS6399069A (ja) | 1985-10-18 | 1988-04-30 | Shionogi & Co Ltd | 縮合イミダゾピリジン誘導体 |
US4753951A (en) | 1985-10-18 | 1988-06-28 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives useful as psychotropic agents |
EP0277794A2 (en) | 1987-02-02 | 1988-08-10 | Ohmeda Pharmaceutical Products Division Inc. | N-heterocyclic-N-(4-piperidyl) amides |
JPH02167265A (ja) | 1988-09-30 | 1990-06-27 | Chugai Pharmaceut Co Ltd | 新規な3,4―ジアミノキノリン及びピリジン系化合物 |
EP0381422A1 (en) | 1989-02-02 | 1990-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Tetrahydrobenzimidazole derivatives |
US5019574A (en) | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
JPH07252228A (ja) | 1994-02-07 | 1995-10-03 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
WO1996011930A1 (en) | 1994-10-18 | 1996-04-25 | Smithkline Beecham P.L.C. | Cns-active pyridinylurea derivatives |
WO1996013485A1 (en) | 1994-10-27 | 1996-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
WO1997014681A1 (en) | 1995-10-16 | 1997-04-24 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as h+-atpases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE590239C (de) * | 1931-08-19 | 1933-12-28 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von quaternaeren Abkoemmlingen heterocyclischer Stickstoffverbindungen |
DE947552C (de) * | 1944-04-18 | 1956-09-06 | Hoechst Ag | Verfahren zur Herstellung von 4-Aminochinaldinverbindungen |
GB1185539A (en) * | 1967-11-03 | 1970-03-25 | Smith & Nephew | Substituted Tetrazoles |
AU638840B2 (en) * | 1990-07-05 | 1993-07-08 | Sumitomo Chemical Company, Limited | Pyrimidine derivative |
-
1999
- 1999-03-23 US US09/646,781 patent/US6410561B1/en not_active Expired - Fee Related
- 1999-03-23 TR TR2000/03598T patent/TR200003598T2/xx unknown
- 1999-03-23 RU RU2000126841/04A patent/RU2202344C2/ru not_active IP Right Cessation
- 1999-03-23 ID IDW20002152A patent/ID26099A/id unknown
- 1999-03-23 CN CN99806429A patent/CN1301154A/zh active Pending
- 1999-03-23 SK SK1427-2000A patent/SK14272000A3/sk unknown
- 1999-03-23 EP EP99909320A patent/EP1072263A4/en not_active Withdrawn
- 1999-03-23 IL IL13857399A patent/IL138573A0/xx unknown
- 1999-03-23 AU AU28558/99A patent/AU754716B2/en not_active Ceased
- 1999-03-23 WO PCT/JP1999/001462 patent/WO1999048492A1/ja not_active Application Discontinuation
- 1999-03-23 KR KR1020007010601A patent/KR20010042161A/ko not_active Application Discontinuation
- 1999-03-23 CA CA002325638A patent/CA2325638A1/en not_active Abandoned
- 1999-03-23 NZ NZ507760A patent/NZ507760A/xx unknown
- 1999-03-23 HU HU0101275A patent/HUP0101275A3/hu unknown
- 1999-03-23 BR BR9909666-8A patent/BR9909666A/pt not_active IP Right Cessation
- 1999-03-24 TW TW088104619A patent/TW487571B/zh not_active IP Right Cessation
- 1999-03-26 AR ARP990101349A patent/AR018168A1/es not_active Application Discontinuation
- 1999-03-26 CO CO99018458A patent/CO5080780A1/es unknown
-
2000
- 2000-09-25 FI FI20002103A patent/FI20002103A/fi unknown
- 2000-09-25 NO NO20004778A patent/NO20004778L/no unknown
- 2000-10-20 ZA ZA200005881A patent/ZA200005881B/en unknown
-
2002
- 2002-05-10 US US10/141,866 patent/US6903094B2/en not_active Expired - Fee Related
-
2005
- 2005-06-06 US US11/145,169 patent/US20060030565A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293549A (en) | 1977-11-07 | 1981-10-06 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktion-Saktieselskab) | Quinolinyl guanidines having antiinflammatory, analgesic or antipyretic activity |
JPS5473784A (en) | 1977-11-07 | 1979-06-13 | Leo Pharm Prod Ltd | Substituted quinolylguanidine derivatives and their manufacture and use |
US4839366A (en) | 1983-04-06 | 1989-06-13 | Chiesi Farmaceutici S.P.A. | Methylthioquinolyl guanidine derivative, process of preparation thereof and pharmaceutical compositions therefrom |
JPS59210084A (ja) | 1983-04-06 | 1984-11-28 | キエシ・フアルマチエウチチ・エツセ・ピ・ア | 抗炎症作用を有する化合物、その製法およびそれを有効成分とする医薬 |
JPS62503030A (ja) | 1985-05-07 | 1987-12-03 | アルカロイダ ベギエスゼテイ ギヤル | トリアゾリルキノリン誘導体 |
US5104884A (en) | 1985-05-07 | 1992-04-14 | Alkaloida Vegyeszeti Gyar | Triazolyl quinoline derivatives |
JPS6399069A (ja) | 1985-10-18 | 1988-04-30 | Shionogi & Co Ltd | 縮合イミダゾピリジン誘導体 |
US4753951A (en) | 1985-10-18 | 1988-06-28 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives useful as psychotropic agents |
JPS63264460A (ja) | 1987-02-02 | 1988-11-01 | ビーオーシー インコーポレーテッド | N―複素環―n―(4―ピペリジル)アミド及び該化合物を含む薬剤組成物 |
EP0277794A2 (en) | 1987-02-02 | 1988-08-10 | Ohmeda Pharmaceutical Products Division Inc. | N-heterocyclic-N-(4-piperidyl) amides |
JPH02167265A (ja) | 1988-09-30 | 1990-06-27 | Chugai Pharmaceut Co Ltd | 新規な3,4―ジアミノキノリン及びピリジン系化合物 |
US5019574A (en) | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
EP0381422A1 (en) | 1989-02-02 | 1990-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Tetrahydrobenzimidazole derivatives |
JPH03223278A (ja) | 1989-02-02 | 1991-10-02 | Yamanouchi Pharmaceut Co Ltd | テトラヒドロベンズイミダゾール誘導体 |
JPH07252228A (ja) | 1994-02-07 | 1995-10-03 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
WO1996011930A1 (en) | 1994-10-18 | 1996-04-25 | Smithkline Beecham P.L.C. | Cns-active pyridinylurea derivatives |
WO1996013485A1 (en) | 1994-10-27 | 1996-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
WO1997014681A1 (en) | 1995-10-16 | 1997-04-24 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as h+-atpases |
Non-Patent Citations (5)
Title |
---|
Aries Robert, "Analgesic 3-methylsalicyloylanthranilates," Brevet D'invention, (Feb. 21, 1969; 3 pp.,) 1.557.928 (with abstract). |
Aries Robert, Salicylamidoquinoline Analgesics, "Brevet D'invention", (Oct. 25, 1968; 3pp.) 1.543.405 (with abstract). |
Chu-Tzu Pen and T.C. Daniels "The Synthesis of Some 6-N Substituted Amido Derivatives of 4,6-Diaminoquinaldine and a Study of their in vitro Antibacterial Activity 1.2"; (Report No. PB-981 Jul. 1945), p. 17. |
Dr. Heinrich Jensch, "Guanylhydrazones of the 4-Aminoquinoline series", 10- Organic Chemistry Ger. No. 831.100; 3pp.) (Feb. 11, 1952). |
Dr. Heinrich Jensch, 4-Aminoquinaldine compound 10G-Heterocyclic compound and Chemical Abstract Ger. No. 947.552, Sep. 6, 1956; Cl 12p.). |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US7312234B2 (en) * | 2000-09-15 | 2007-12-25 | Anormed | Chemokine receptor binding heterocyclic compounds |
US20050026942A1 (en) * | 2000-09-15 | 2005-02-03 | Anormed | Chemokine receptor binding heterocyclic compounds |
US20080090846A1 (en) * | 2000-09-15 | 2008-04-17 | Gary Bridger | Chemokine receptor binding heterocyclic compounds |
US7084156B2 (en) * | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
US20050026915A1 (en) * | 2001-11-27 | 2005-02-03 | Devita Robert J. | 2-Aminoquinoline compounds |
US8003669B2 (en) | 2002-03-29 | 2011-08-23 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
US7566728B2 (en) | 2002-03-29 | 2009-07-28 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
US20050119308A1 (en) * | 2002-03-29 | 2005-06-02 | Koji Teshima | Remedy for sleep disturbance |
US20040092513A1 (en) * | 2002-08-07 | 2004-05-13 | Aventis Pharma Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7105513B2 (en) | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
WO2004063330A2 (en) | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | (2-carboxamido) (3-amino) thiophene compounds |
US20060247275A1 (en) * | 2003-01-06 | 2006-11-02 | Crew Andrew P | (2-carboxamido)(3-amino)thiophene compounds |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US6949563B2 (en) | 2003-01-06 | 2005-09-27 | Graham Michael Wynne | (2-carboxamido)(3-amino)thiophene compounds |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
US20040186124A1 (en) * | 2003-01-06 | 2004-09-23 | Wynne Graham Michael | (2-carboxamido)(3-amino)thiophene compounds |
US7524859B2 (en) | 2003-01-06 | 2009-04-28 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino)thiophene compounds |
US7312044B2 (en) | 2003-03-07 | 2007-12-25 | The Trustees Of Columbia University In The City Of New York | Type 1 ryanodine receptor-based methods |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US20070287751A1 (en) * | 2004-03-12 | 2007-12-13 | De La Torre Marta G | Opioid Receptor Antagonists |
US7381750B2 (en) * | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
WO2006047574A1 (en) | 2004-10-26 | 2006-05-04 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-amino) thiophene compounds |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20090176838A1 (en) * | 2006-01-30 | 2009-07-09 | Purdue Pharma L.P. | Cyclourea Compounds as Calcium Channel Blockers |
US8354434B2 (en) | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
US8722731B2 (en) | 2010-06-07 | 2014-05-13 | Novomedix, Llc | Furanyl compounds and the use thereof |
US9149527B2 (en) | 2010-06-07 | 2015-10-06 | Novomedix, Llc | Furanyl compounds and the use thereof |
US9663483B2 (en) | 2010-06-07 | 2017-05-30 | Novomedix, Llc | Furanyl compounds and the use thereof |
US8895606B2 (en) | 2010-08-24 | 2014-11-25 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9000029B2 (en) | 2010-08-24 | 2015-04-07 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9211279B2 (en) | 2010-08-24 | 2015-12-15 | Actelion Pharmaceuticals Ltd. | Proline sulfonamide derivatives as orexin receptor antagonists |
US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
WO2019020248A1 (de) * | 2017-07-24 | 2019-01-31 | Beiersdorf Ag | Verwendung von n-(4-amino-2-methylchinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamid zur herstellung von kosmetischen oder dermatologischen zubereitungen zur behandlung und/oder prophylaxe der symptome der intrinsischen und/oder extrinsischen hautalterung sowie zur behandlung und prophylaxe der schädlichen auswirkungen ultravioletter strahlung auf die haut |
Also Published As
Publication number | Publication date |
---|---|
ID26099A (id) | 2000-11-23 |
CA2325638A1 (en) | 1999-09-30 |
AR018168A1 (es) | 2001-10-31 |
SK14272000A3 (sk) | 2001-05-10 |
BR9909666A (pt) | 2001-09-11 |
EP1072263A1 (en) | 2001-01-31 |
HUP0101275A3 (en) | 2002-12-28 |
ZA200005881B (en) | 2001-08-23 |
RU2202344C2 (ru) | 2003-04-20 |
US6903094B2 (en) | 2005-06-07 |
NZ507760A (en) | 2002-10-25 |
TR200003598T2 (tr) | 2001-06-21 |
FI20002103A (fi) | 2000-11-17 |
TW487571B (en) | 2002-05-21 |
AU2855899A (en) | 1999-10-18 |
AU754716B2 (en) | 2002-11-21 |
CN1301154A (zh) | 2001-06-27 |
US20060030565A1 (en) | 2006-02-09 |
NO20004778L (no) | 2000-11-27 |
HUP0101275A2 (hu) | 2001-09-28 |
CO5080780A1 (es) | 2001-09-25 |
KR20010042161A (ko) | 2001-05-25 |
US20030055087A1 (en) | 2003-03-20 |
WO1999048492A1 (fr) | 1999-09-30 |
IL138573A0 (en) | 2001-10-31 |
EP1072263A4 (en) | 2004-03-31 |
NO20004778D0 (no) | 2000-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410561B1 (en) | Amide derivatives and nociceptin antagonists | |
JP7168773B2 (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
CA2922077C (en) | Quinoline-substituted compound | |
WO2001025228A1 (fr) | Derives d'amines | |
KR20040048995A (ko) | 퀴놀린 화합물 | |
WO2001021615A1 (en) | Benzimidazole derivatives | |
CA2554774A1 (en) | Novel heterocyclic compound | |
WO2014040549A1 (zh) | 炔杂芳环化合物及其应用 | |
US20100324017A1 (en) | Acylguanidine derivative | |
KR20080021134A (ko) | 5-ht1a 수용체의 피페라진-피페리딘 길항제 및 효능제 | |
US11466012B2 (en) | Tetrahydroisoquinoline compounds | |
JP3253077B2 (ja) | ヒドロイソキノリン誘導体 | |
JP3013989B2 (ja) | アミド誘導体及びノシセプチンアンタゴニスト | |
CN109666022B (zh) | 三氮唑衍生物及其制备方法和用途 | |
WO2006132192A1 (ja) | 新規2-キノロン誘導体 | |
CN113527311A (zh) | Fgfr4抑制剂、组合物及其在药物制备中的用途 | |
US20170007610A1 (en) | Novel heterobicyclic compounds as kappa opioid agonists | |
TW201922726A (zh) | 突變之表皮生長因子受體(egfr)族群之酪胺酸激酶抑制劑 | |
MXPA00009438A (en) | Amide derivatives and nociceptin antagonists | |
CN107383002B (zh) | 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途 | |
CZ20003448A3 (cs) | Antagonista nociceptinu, derivát amidu, farmaceutický prostředek, způsob, použití a komerční balení | |
KR20220044721A (ko) | 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물 | |
CA3181590A1 (en) | Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JAPAN TOBACCO INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHINKAI, HISASHI;ITO, TAKAO;YAMADA, HIDEKI;REEL/FRAME:011166/0910 Effective date: 20000918 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20060625 |